Experts Call Upon Governments To Recommend Higher Doses Of Vitamin D Intake To Fight COVID-19
LONDON (dpa-AFX) - A group of over 100 scientists, doctors and health experts from across the globe have written an open letter calling for increased use of Vitamin D to fight the SARS-CoV-2 infection.
The Open Letter calls on all governments, public health officials, doctors, and healthcare workers to recommend daily Vitamin D intake of 4000 IU (100mcg) for adults. According to the signatories, there is ample scientific evidence to suggest that low Vitamin D levels almost certainly promote COVID-19 infections, hospitalizations, and deaths .
On December 17, the UK s National Institute for Health and Care Excellence (NICE) issued a guideline concluding that there was little evidence for using Vitamin D supplements to prevent or treat COVID-19.
NICE Publishes Briefing on Saluda s Evoke Closed-Loop Spinal Cord Stimulation (SCS) System
ARTARMON, Australia, Dec. 22, 2020 /PRNewswire/ Saluda Medical Pty Limited ( Saluda Medical ) announced today that the UK s National Institute for Health and Care Excellence (NICE) issued a Medtech Innovation Briefing (MIB) titled Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain. The MIB states Evoke would be used as a replacement option or alternative to current open-loop (fixed-output) spinal cord stimulation therapy in people with leg and back pain.
The Evoke Closed-Loop SCS System is the first and only SCS technology designed to measure the spinal cord s response to stimulation and make real-time, automatic adjustments intended to remain in the therapeutic range and provide long-term pain relief.
UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme
The antibiotic treats infections caused by aerobic Gram-negative bacteria
Shionogi’s novel antibiotic Fetcroja has been selected for inclusion in a pilot subscription reimbursement scheme, launched by the UK’s National Institute for Health and Care Excellence (NICE) and NHS England and Improvement (NHSE&I).
The scheme – first announced by Health Secretary Matt Hancock in 2019 – will pilot a model that reimburses pharma companies for antimicrobials based on a health technology value assessment of their value to the NHS, as opposed to the volumes of the drug used.
This pilot is intended to encourage drug developers to resume and increase research and development into new antibiotic medications, given that this area is lacking in innovation due to the economic challenges associated with it.
Insane Medicine, Chapter 5: The Manufacture of Childhood Depression (Part 2) madinamerica.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from madinamerica.com Daily Mail and Mail on Sunday newspapers.
NICE recommends Novartis’ wet AMD drug Beovu
16th December 2020
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ anti-VEGF treatment Beovu (brolucizumab) for routine NHS use in wet age-related degeneration (AMD) patients.
The final appraisal determination (FAD) recommendation was based on the results from Novartis’ phase III HAWK and HARRIER trials, in which Beovu met the primary endpoint.
This included demonstrating improvements in best-corrected visual acuity (BCVA) from baseline that were non-inferior to Bayer’s Eylea (aflibercept) at week 48.
Additionally, approximately 30% of Beovu-treated patients gained at least 15 letters at week 48 and vision gain was observed as early as four weeks into the trial and sustained over the course of the study.